FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Impel NeuroPharma, Inc Granted U.S. FDA Approval for its Acute Migraine Treatment”
“The Buzz'' Show: Impel NeuroPharma, Inc. Granted U.S. FDA Approval for its Acute Migraine Treatment
Impel NeuroPharma, Inc. (NASDAQ: IMPL) surged over 46% in premarket trading after the company announced that the U.S. FDA approved the TRUDHESA™ nasal spray for the acute treatment of migraine with or without aura in adults.
Previously known as INP104, TRUDHESA is the first and only therapeutic to use POD technology to deliver dihydroergotamine mesylate to the vascular-rich upper nasal space, offering rapid, sustained, and consistent symptom relief without injection or infusion.
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to TRUDHESA™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
For more "The Buzz" please visit: https://bit.ly/2Rlh4zH
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
© 2011 Financial Buzz. All rights reserved. No portion of this video or FinancialBuzz.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law.
FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform.
0 Comments